BlackRock, Inc. disclosed two transparency notifications regarding its holdings in Fagron NV. On May 11, 2026, BlackRock's stake in Fagron rose above the 3% threshold, holding 3.01% of voting rights with 2,072,188 shares plus 145,030 financial instruments. However, by May 12, 2026, their stake fell below 3% to 2.89%, holding 1,990,401 shares with the same number of financial instruments. These changes reflect minor adjustments in BlackRock's voting rights in Fagron, a pharmaceutical company listed on Euronext Brussels and Amsterdam. The notifications are part of regulatory transparency requirements and do not indicate a major strategic shift.
BlackRock reported strong Q2 results with net inflows of $192 billion, pushing assets under management (AUM) to a record $15.3 trillion. The firm's ETF business showed strong momentum, supported by new product launches and inclusion in Trump accounts...
BlackRock, Inc. reported a strong second quarter marked by record inflows, increased base fees, and double-digit revenue growth, highlighting the strength of its business model. The company's expansion into private markets and technology services is ...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
BlackRock reported Q2 adjusted earnings of $13.91 per share, surpassing analyst estimates of $12.57, driven by record net inflows of $191.7 billion and a 31% revenue increase to $7.08 billion. Assets under management rose 22% to $15.34 trillion, with...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
